• Patients diagnosed with the 8th Edition of the Tumor, Node, Metastasis (TNM) staging system for Lung Cancer approved by International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC): IV (Any T, Any N, M1a-c)
• Histologically confirmed NSCLC (adenocarcinoma)
• Performance status of 0-2 (ECOG PS)
• Estimated life expectancy ≥3 months
• Treatment naïve patients (chemotherapy, immunotherapy, targeted therapy, radiotherapy).
• Smokers or Non-Smokers

• Patients diagnosed with the Tumor, Node, Metastasis (TNM) staging system for Colorectal Cancer approved by the American Joint Committee on Cancer (AJCC): IV (Any T, Any N, M1a-c).
• Histologically confirmed CRC (adenocarcinoma).
• Performance status of 0-2 (ECOG PS)
• Estimated life expectancy ≥3 months
• Treatment naïve patients (chemotherapy, immunotherapy, targeted therapy, radiotherapy).

The blood will be collected and sent to Tempus Labs using the standard sample collection kit containing all the necessary elements to guarantee shipment to Tempus Labs. Two Streck tubes with 8.5mL of blood per tube will be sent to Tempus Labs.

The ctDNA isolation and automatic library preparation will be performed using TEMPUS technology (Finkel et al 2021).

The NGS analyses will be developed using the xF Tempus assay. This assay involves a panel with hybrid gene capture that detects actionable oncologic targets in four variant classes: single-nucleotide variants (SNVs), insertions/deletions (indels), copy number variants (CNVs), and gene rearrangements. The NGS sequencing is performed using NovaSeq 6000Dx Sequencing System (Illumina, Inc) equipment, according to Tempus protocols. (Finkel et al 2021).

Proportion of patients with at least one actionable variant (%)